Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech.
Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization
Contract partners must help innovator biotechs consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.